To investigate the effects of AZA on the immunopeptidome of AML, we selected four cell lines (THP-1, MOLM-13, SKM-1, and OCI-AML3) belonging to aggressive FAB types (M4/M5) and covering different but frequent mutational statuses (MLL-AF9, FLT3-ITD, TET2 (L1418fs), and NPM1c + DNMT3A (R882C), respectively). This evidence concerns the gene FLT3 and acute myeloid leukemia.